SCIASCIA THOMAS 4
4 · Trevi Therapeutics, Inc. · Filed May 31, 2024
Insider Transaction Report
Form 4
SCIASCIA THOMAS
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-29$2.19/sh+59,354$129,985→ 267,801 total - Sale
Common Stock
2024-05-29$2.55/sh−53,368$136,110→ 214,433 total - Exercise/Conversion
Stock Option (right to buy)
2024-05-29−59,354→ 0 totalExercise: $2.19Exp: 2024-07-01→ Common Stock (59,354 underlying)
Footnotes (4)
- [F1]Includes 14,723 shares purchased through the Issuer's employee stock purchase plan.
- [F2]This sale represents the sale of shares necessary to cover the cost of exercise and to meet tax withholding obligations as a result of the exercise of stock options on May 29, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]This option was granted on July 2, 2014. The 59,354 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.